Positron emission tomography/computed tomography in patients with hepatocellular carcinoma undergoing liver transplantation. Useful,necessary or irrelevant?

Hepatocellular Carcinoma (HCC) is an aggressive tumor entity, with the only curative options being surgical resection or orthotopic liver transplantation (OLT). The presence of one single tumor nodule of less than 5 centimeters diameter or a maximum of 3 nodules, with the largest of these not exceeding 3 centimeters (Milan criteria) constitute the clinical situation in which the best results for OLT in patients with HCC have been achieved. The survival of patients fulfilling the Milan criteria after transplantation is comparable to patients with similar tumor stages without cirrhosis, undergoing hepatic resection. The application of PET in oncology has become increasingly common in the last decade as it is a non-invasive tool that also gathers information about the degree of the biological aggressiveness of the tumor. The objective of this study was to perform a review of the literature, identifying the strengths and weaknesses of the PET as a prognostic tool in patients with HCC after OLT.     

Benign or malignant?: differentiating breast lesions with computed tomography attenuation values on dynamic computed tomography mammography

OBJECTIVE: To evaluate enhancement effects of breast lesions with dynamic computed tomography (CT) and to determine characteristics to aid in differential diagnosis of benign and malignant lesions. METHODS: One hundred seventy-six women underwent preoperative dynamic CT, in which they were scanned with rapid injection of contrast media (3 mL/s) after 30 seconds and 2 minutes (early and delayed phases, respectively). The CT values and enhancement patterns of malignant lesions (n = 154) were compared with those of benign lesions (n = 22), and the cut point of CT values with the best validity was analyzed. RESULTS: The CT values of malignant lesions were higher than those of benign lesions in both phases (P < 0.0001). The cut point was determined to be 60 Hounsfield units (HU) in the early phase (44% validity, 90% sensitivity). Washout and plateau patterns were more commonly seen in the malignant group (73% specificity). CONCLUSIONS: The analysis of enhancement effects on CT may lead to more appropriate differentiation of benign and malignant lesions.     

Can fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography detect hepatocellular carcinoma and its extrahepatic metastases?

Aims

The point of this research is to investigate the potential role of (18-F-FDG/PET) in the identification of hepatocellular carcinoma (HCC) and its metastases.

Size-specific dose estimates: Localizer or transverse abdominal computed tomography images?

AIM: To investigate effect of body dimensions obtained from localizer radiograph and transverse abdominal computed tomography (CT) images on Size Specific Dose Estimate.METHODS: This study was approved by Institutional Review Board and was compliant with Health Insurance Portability and Accountability Act. Fifty patients with abdominal CT examinations (58 ± 13 years, Male:Female 28:22) were included in this study. Anterior-posterior (AP) and lateral (Lat) diameters were measured at 5 cm intervals from the CT exam localizer radiograph (simple X-ray image acquired for planning the CT exam before starting the scan) and transverse CT images. Average of measured AP and Lat diameters, as well as maximum, minimum and mid location AP and Lat were measured on both image sets. In addition, off centering of patients from the gantry iso-center was calculated from the localizers. Conversion factors from American Association of Physicists in Medicine (AAPM) report 204 were obtained for AP, Lat, AP + Lat, and effective diameter (√ AP * Lat) to determine size specific dose estimate (SSDE) from the CT dose index volume (CTDI_vol) recorded from the dose reports. Data were analyzed using SPSS v19.RESULTS: Total number of 5376 measurements was done. In some patients entire body circumference was not covered on either projection radiograph or transverse CT images; hence accurate measurement of AP and Lat diameters was not possible in 11% (278/2488) of locations. Forty one patients were off-centered with mean of 1.9 ± 1.8 cm (range: 0.4-7 cm). Conversion factors for attained diameters were not listed on AAPM look-up tables in 3% (80/2488) of measurements. SSDE values were significantly different compared to CTDI_vol, ranging from 32% lower to 74% greater than CTDI_vol.CONCLUSION: There is underestimation and overestimation of dose comparing SSDE values to CTDI_vol. Localizer radiographs are associated with overestimation of patient size and therefore underestimation of SSDE.     

Imaging suspected cervical spine injury: Plain radiography or computed tomography? Systematic review

Aim(1) to establish which modality offers the greatest accuracy in the detection of cervical spine injury (CSI) Following trauma: plain radiography or computed tomography (CT), and (2) make an evidence-based recommendation for the initial imaging modality of choice.MethodA systematic literature review was performed to identify primary research studies which compare the diagnostic accuracy of plain radiography and CT with the results of a reference standard in the detection of CSI. A search of MEDLINE, EMBASE, CINAHL, Science Direct and Pubmed Central databases was conducted.ResultsTen studies were identified. Critical appraisal identified limitations among all studies. There was heterogeneity in the sensitivity estimates for plain radiography, whereas estimates for CT were consistently high. Examination of the reported sensitivities shows that CT outperforms plain radiography in the detection of CSI.ConclusionCT is superior to plain radiography in the detection of CSI. However, the optimal imaging strategy depends on the patients' relative risk of injury. If at high-risk cervical CT is indicated. If at low-risk the increased cost and radiation exposure mean that screening CT may not be warranted, good-quality plain radiographs are sufficient.     

Vascular invasion in hepatocellular carcinoma: is there a correlation with MRI?

Objective

Hepatocellular carcinoma (HCC) is one of the commonest malignancies worldwide. Prognosis is predicted by size at diagnosis, vascular invasion and tumour proliferation markers. This study investigates if MRI features of histologically proven HCCs correlate with vascular invasion.

Methods

Between 2006 and 2008, 18 consecutive patients, with a total of 27 HCCs, had comprehensive MRI studies performed at our institution within a median of 36 days of histology sampling. Each lesion was evaluated independently on MRI by 3 radiologists (blinded to both the radiology and histopathology reports) using a 5-point confidence scale for 23 specific imaging features. The mean of the rating scores across readers was calculated to determine interobserver consistency. The most consistent features were then used to examine the value of features in predicting vascular invasion, using a χ² test for trend, having eliminated those features without sufficient variability.

Results

22 of the 23 imaging features showed sufficient variability across lesions. None of these significantly correlated with the presence of vascular invasion, although a trend was identified with the presence of washout in the portal venous phase on MRI and the median size of lesions, which was greater with vascular invasion.

Conclusion

This study suggests that no single MRI feature accurately predicts the presence of vascular invasion in HCCs, although a trend was seen with the presence of washout in the portal venous phase post gadolinium. Larger prospective studies are required to investigate this further.Hepatocellular carcinoma (HCC) is one of the commonest malignancies worldwide, either arising de novo or on a background of cirrhosis. The incidence in Western countries is rising owing to increasing rates of alcoholic liver disease and hepatitis C infection. Untreated, the 5-year survival rate for symptomatic HCC is less than 5% [1]. At present, surgery is the only potentially curative treatment for HCC with options including either a partial hepatectomy or orthotopic liver transplantation (OLT). Following resection there is a 5-year survival rate of 40–50% [2] with a cumulative 5-year recurrence rate between 75 and 100% [3]. The 5-year survival rate in patients with cirrhosis following transplantation of small (<2 cm) HCC is up to 80% [4]. However, the use of OLT is limited owing to the lack of donor livers. Regional therapies such as transcatheter arterial chemoembolisation [5] and percutaneous radiofrequency ablation [6] may improve prognosis. The value of neo-adjuvant and adjuvant chemotherapy and immunotherapy in prolonging survival remains controversial [7,8]. However, a recent study evaluating sorafenib, a multikinase inhibitor, in patients with advanced HCC has shown an increased median overall survival of 2.8 months over a placebo [9].Studies of patients with explanted liver for end-stage cirrhosis have shown that MRI, with the use of dynamic gadolinium-enhanced sequences, has a moderate sensitivity for the detection of HCC of between 55 and 91% [10-12] and specificity between 55 and 86% [11-13]. The sensitivity is lower with lesions <2 cm in size [11-13]. In patients with cirrhosis, HCC is thought to develop as part of a spectrum of de-differentiation from regenerative nodule through to low-grade dysplastic nodule, high-grade dysplastic nodule, then to frankly malignant. Early diagnosis using non-invasive imaging leads to an improved prognosis but at present, unless biopsy is performed, only lesion size is used to determine patient management in those where gross vascular involvement or metastatic spread precludes curative treatment.Several factors predicting outcome have been identified including tumour pathological factors (such as size, stage, grade, the presence of vascular invasion, portal vein tumour thrombus and intrahepatic metastases) [14,15], the patient’s hepatitis status, the patient’s functional liver reserve [16] and the serum α-fetoprotein level [17]. Overall, one of the most strongly correlated factors is the presence or absence of vascular invasion. There is a 4.4- and 15-fold increased risk of recurrence following OLT for HCC in patients with micro- or macrovascular invasion, respectively [18].The aims of this retrospective study were twofold. First to identify the interobserver variability of MRI features for patients with histologically proven HCC, and second to determine if there was a correlation between imaging features on MRI and histologically defined vascular invasion; these MRI features could then serve as a surrogate marker of prognosis. There has been little literature to date attempting to correlate MRI features with microvascular invasion.     

Mesenteric cysts associated with recurrent small-bowel volvulus: cause or effect?

Recurrent small-bowel volvulus is a state of recurrent intermittent or long-standing persistent twisting of small-bowel loops around its mesentery. The association of mesenteric cysts with recurrent small-bowel volvulus as the cause or effect is a much debated issue in the literature. We report two cases of mesenteric lymphangioma and one case of enteric duplication cyst seen in association with recurrent small-bowel volvulus of long duration in absence of malrotation.     

Post mortem computed tomography: Useful or unnecessary in gunshot wounds deaths? Two case reports

Post-mortem computer tomography (PMCT) is currently an useful procedure that can elucidate patterns of injuries, providing strong medical evidence that is very useful during litigation and at trial. This technique is especially useful in gunshot wounds cases, allowing an easier location and retrieval of the bullet and/or its fragments inside the body. In such cases, the use of 3D rendering can be very useful in order to obtain essential information, such as: accurate depict of the wound track, discerning between entrance and exit wounds, show bone’s fracture and its fragments course inside the body. The authors performed analysis on two cases of death by gunshot wounds, and a PMCT before the postmortem examination was made. The obtained CT scans were evaluated using the open-source software OsiriX on a Mac OS X computer, performing 3D rendering of the DICOM images. The crime scene reconstruction was performed using the software Poser Debut® on a Mac OS X computer. In both cases, PMCT showed multiple advantages: objectivity, reproducibility, ease visualization of the wound paths, easy localization of bullet and their fragments, allowing us to clarify the cause of death before the traditional autopsy. PMCT should became a standard in forensic practice as an aid to the tradition postmortem examination to obtain as much information as possible in order to clarify the cause and manner of death.     

Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography?

The usefulness and complementarity of gallium (67Ga) scintigraphy and computed tomography (CT) in the management of patients with lymphoma have been extensively demonstrated. Owing to a lack of anatomical landmarks and physiological distribution of the tracer, precise localisation of abnormalities on 67Ga scintigraphy can be difficult. As fusion imaging techniques between single-photon emission tomography (SPET) and CT have been developed recently, we investigated whether use of CT/67Ga SPET fusion imaging could help in the interpretation of 67Ga scintigraphy. From November 1999 to May 2001, 52 consecutive fusion studies were performed in 38 patients [22 patients with Hodgkin's disease (HD) and 16 patients with non-Hodgkin's lymphoma (NHL)] as part of pre-treatment staging (n=13), treatment evaluation (n=20) or evaluation of suspected recurrence (n=19). 67Ga scintigraphy was carried out 2 and 6 days following the injection of 185-220 MBq 67Ga citrate. On day 2, 67Ga SPET and CT were performed, focussing on the chest and/or the abdomen/pelvis. Data from each imaging method were co-registered using external markers. 67Ga scintigraphy and CT were initially interpreted independently by nuclear medicine physicians and radiologists. CT/67Ga SPET fusion studies were then jointly interpreted and both practitioners indicated when fusion provided additional information in comparison with CT and 67Ga SPET alone. Image fusion was considered to be of benefit in 12/52 (23%) studies which were performed for initial staging (n=4), treatment evaluation (n=4) or evaluation of suspected recurrence (n=4). In these cases, image fusion allowed either confirmation and/or localisation of pathological gallium uptake (n=10) or detection of lesions not visible on CT scan (n=2). Fusion was relevant for discrimination between osseous lesions and lymph node involvement adjacent to bone, especially in the thoracic and lumbar spine and pelvis. In the abdomen and pelvis, fusion helped to differentiate physiological bowel elimination from abnormal uptake, and assisted in precisely locating uptake in neighbouring viscera of the left hypochondrium, including the spleen, left liver lobe, coeliac area, stomach wall and even the splenic flexure. At the thoracic level, fusion also proved useful for demonstrating clearly the relationships of abnormal foci to the pleura, hepatic dome, mediastinum, ribs or thoracic spine. Clinical management was altered by fusion imaging in one patient (chemotherapy was given instead of radiotherapy) and was potentially affected in three other patients (in that, in conjunction with other factors, the results of fusion imaging had an influence on the decision regarding use of irradiation and especially the treatment volume). In conclusion, CT/67Ga SPET fusion imaging allowed precise localisation of gallium uptake and correct attribution to the involved viscera, thereby altering the diagnosis in 20%-25% of studies in comparison with CT and 67Ga SPET analyses alone. CT/67Ga SPET fusion therefore appears valuable in facilitating the interpretation of 67Ga scintigraphy and we recommend its use in patients with lymphoma when CT and 67Ga scintigraphy are planned.     

Isolated cerebral susceptibility artefacts in patients with malignant melanoma: metastasis or not?

Objective

While staging patients with malignant melanoma, cerebral susceptibility artefacts on T2*-weighted/susceptibility-weighted imaging (SWI) sequences without a correlate on contrast-enhanced T1-weighted images can be confusing. Without intravenous contrast enhancement, cavernomas, microhaemorrhages and melanin-containing metastases represent possible differential diagnoses for these findings. The purpose of this study was to find out, how often such lesions correspond to metastases.

Methods

Brain MR images (1.5 T) of 408 patients with malignant melanoma but without cerebral metastases in the initial staging by MRI were reviewed retrospectively. Eighteen patients (5 female, 13 male) with malignant melanoma and signal intensity loss on T2*/SWI were included in our study. The average observation period was 19.6 months (6–46 months, 2006–2009).

Results

In each of these 18 patients between one and seven hypointense lesions on T2*/SWI were found. None of these lesions developed into metastasis.

Conclusion

Focal areas of susceptibility artefacts in the brain parenchyma without corresponding abnormalities in contrast-enhanced T1 weighted images are unlikely to represent brain metastases.

Key Points

? In melanoma patients early diagnosis of metastatic brain lesions is mandatory. ? Melanin content and haemorrhage are potential reasons for MRI characteristics of melanoma metastases. ? Susceptibility-weighted MRI visualises melanin and blood products. ? Isolated cerebral susceptibility artefacts do not convert into melanoma metastases. ? SWI/T2* sequences cannot replace Gd-enhanced sequences.     

Combined head and abdominal computed tomography for blunt trauma: which patients with minor head trauma benefit most?

The widespread availability of computed tomography (CT) in the diagnosis and management of blunt trauma has created the possibility of overuse without clear indications. Some clinicians believe that patients with head injury, intoxication, and/or distracting injury have an unreliable abdominal examination and should undergo combined head and abdomen CT. The objective of this study was to evaluate which patients with minor head trauma benefit most from combined head and abdomen CT. Consecutive blunt trauma patients, with a Glasgow coma scale (GCS) of 14 or 15, who underwent concomitant head and abdomen CT upon admission to a level I trauma center over a 2-year period were retrospectively reviewed. Patient demographics, mechanism of injury, physical exam, hospital course, and radiological and laboratory findings were recorded. Patients were divided into four subgroups based upon the presence or absence of intracranial and/or intraabdominal injury detected by CT. Among the 1,478 blunt head trauma patients, only 18 (1%) patients had both head and abdominal injuries detected by combined CT. One-hundred twelve (8%) patients had only head injuries, and 131 (9%) had only intraabdominal injuries detected. Patients with a GCS of 14 were more likely to have isolated head injury [odds ratio (OR) 3.1, P=0.001], while those with loss of consciousness were more likely to have combined head and intraabdominal injury (OR 6.8, P=0.03) or isolated head injury (OR 1.7, P=0.02). Abdominal tenderness was associated with increased risk of isolated intraabdominal injury (OR 1.8, P=0.0015). Hematuria was associated with increased risk of combined head and intraabdominal injury (OR 8.3, P=0.0004) or isolated intraabdominal injury (OR 7.9, P=0.0001). Patients with loss of consciousness and/or GCS of 14 frequently undergo head CT. The addition of an abdomen CT scan in this patient population should be based on objective clinical criteria such as presence of abdominal tenderness and/or hematuria.This work was presented at the Society of Academic Emergency Medicine Annual Meeting, San Francisco, May 20, 2006.     

Abdominal imaging findings on computed tomography in patients acutely infected with SARS-CoV-2: what are the findings?

Emergency Radiology - To investigate what findings are new on contrast-enhanced abdominopelvic CT in patients infected with SARS-CoV-2. Contrast-enhanced CT of the abdomen and pelvis of patients...     

Granulomatous disease: is it a nuisance or an asset during PET/computed tomography evaluation of lung cancers?

OBJECTIVES: To evaluate combined PET-computed tomography (CT) criteria for differentiating between granulomatous disease (GD) and malignancy (CA) in oncologic PET-CT studies. METHODS: Sixty-two patients who were referred for fluoro-2-deoxyglucose (FDG) PET-CT evaluation of pulmonary lesion(s) without a history of concurrent infection were studied. PET-CT was performed 1.5 h after intravenous administration of 555 MBq 18F-FDG in the fasting state with oral contrast. Combined PET-CT criteria including (i) calcifications (Ca2+) within lymph nodes, (ii) Ca2+ in lung nodules, (iii) liver and/or spleen Ca2+, (iv) locations of lung lesion(s), (v) hilar FDG uptake, (vi) comparison of lung versus maximum mediastinal FDG uptake, (vii) lymph node uptake not in the most probable lymphatic drainage pathway from a particular lung lesion, and (viii) extra pulmonary abnormal FDG uptake were each assigned a numerical score (0-3) with progressively higher score and sum of scores toward the increasing likelihood of GD. These patients either had pathological confirmation by biopsy/resection or were followed radiographically for a period of 2 years (CA=13; GD=49). Discriminant analysis was performed on all the above criteria with this gold standard. Simple t-test and box plot analysis were also performed on the summation of the scores (from 0 in CA to 13 in GD). RESULTS: When all eight criteria were entered into discriminant analysis, the combined PET-CT criteria classified correctly 71% of patients with a sensitivity of 65% and specificity of 92% for GD. The most significant discriminating criterion was FDG uptake in the lung lesion(s) less than maximum mediastinal uptake (P=0.01). The sum scores in GD and CA were significantly different (4.9+/-2.4 vs. 3.2+/-1.5, respectively, P=0.014). Box plots showed a clear separation at a cut-off value of around 3.5. CONCLUSION: Results show that the set of combined PET-CT criteria are highly specific for GD, which is not necessarily a nuisance during oncologic evaluation. Knowledge of these criteria may attribute some of the abnormal PET findings to GD, which is a useful asset for quick recognition and clinical interpretation.     

Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT

Objectives

To compare the diagnostic performance of gadoxetic acid-enhanced MRI using 3.0 T with that of multiphasic 64-multirow detector CT (MDCT) for the detection of small (≤2 cm) hepatocellular carcinoma (HCC) in patients with chronic liver disease.

Methods

A total of 54 patients (44 men, 10 women; age range, 33–81 years) with 59 HCCs (≤2 cm in diameter) who underwent both multiphasic (arterial, portal venous, equilibrium) 64-MDCT and gadoxetic acid-enhanced 3.0 T MRI were enrolled in this study. Two observers independently and randomly reviewed the MR and CT images on a lesion-by-lesion basis. The diagnostic performance of these techniques for the detection of HCC was assessed by alternative free-response receiver operating characteristic (ROC) analysis, in addition to evaluating the sensitivity and positive predictive value.

Results

For each observer, the areas under the ROC curve were 0.874 and 0.863 for MRI, respectively, as opposed to 0.660 and 0.687 for CT, respectively. The differences between the two techniques were statistically significant for each observer (p<0.001). The sensitivities (89.8% and 86.4%) of MRI for both observers were significantly higher than those (57.6% and 61.0% for each observer, respectively) of MDCT. No significant difference was seen between the positive predictive values for the two techniques (p>0.05).

Conclusion

Gadoxetic acid-enhanced 3.0 T MRI shows a better diagnostic performance than that of 64-MDCT for the detection of small (≤2 cm) HCCs in patients with chronic liver disease.Hepatocellular carcinoma (HCC) is associated with underlying chronic liver disease in more than 90% of cases, and constitutes the leading cause of death in patients with chronic liver disease [1,2]. Therefore, early detection and accurate assessment of small HCC are of great importance when planning the most appropriate therapeutic approach. The efficacy of various treatments and the survival of patients with small HCC are much more successful than those for patients with larger tumours. The typical imaging feature of HCC on one or two dynamic studies, including either CT scanning, contrast-enhanced ultrasound or MRI, has been used to establish the diagnosis of HCC according to the size of the lesion (1–2 cm or >2 cm in diameter) in patients with chronic liver disease [3,4]. With a state-of-the-art imaging technique, the detection of smaller lesions in the liver may be possible. However, there is still great difficulty in the characterisation of hypervascular nodules <2 cm in diameter, which often have non-specific imaging characteristics [5].The use of multirow detector CT (MDCT), which has advantages that include greater speed, thinner slices and multiphasic scanning, has improved the chance of detecting HCC [6,7]. The diagnostic performance of liver MRI for detecting and characterising focal hepatic lesions has also been improved with the development of MRI technologies and MR contrast media [8,9]. Recently, a widely used liver-specific contrast agent, gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (gadoxetic acid disodium; Primovist, Bayer Schering Pharma, Berlin, Germany) has produced both dynamic and liver-specific hepatobiliary MR images. This contrast agent is highly liver specific with approximately 50% of the injected dose taken up by functioning hepatocytes and excreted in bile, which enables hepatobiliary phase imaging to start at 10–20 min post injection, and hence makes it more suitable for use in clinical practice [10-12]. On the other hand, another gadolinium-based hepatobiliary agent, gadobenate dimeglumine (Gd-BOPTA/Dimeg; Multihance, Bracco, Milan, Italy), has approximately 3–5% of the injected dose taken up by functioning hepatocytes and excreted in bile, and enables hepatobiliary phase imaging to start at more than 60 min. However, a previous study [13] demonstrated that the diagnostic performance of gadoxetic acid-enhanced MRI and gadobenate dimeglumine-enhanced MRI for pre-operatively detecting HCC is quite similar. In addition to liver-specific contrast agent, high-field-strength (3.0 T) MRI may possibly be better than 1.5 T due to the advantages of greater signal-to-noise ratio (SNR) and image quality than 1.5 T MRI, thus improving lesion detection (although there are substantial challenges with 3 T in abdominal imaging). The purpose of this study was to compare the diagnostic performance of gadoxetic acid-enhanced MRI using 3.0 T with that of triple-phase 64-MDCT for the detection of small (≤2 cm in diameter) HCC in patients with chronic liver disease.